Tuesday November 21, 2000

COMPANY PRESS RELEASE

Transgenomic Expands Sales and Marketing Leadership with Key Management Changes

Appointments Reflect Company's Continued Growth and Global Market Expansion

SAN JOSE, Calif., and OMAHA, Neb., (November 21, 2000) - Transgenomic (Nasdaq:TBIO) today announced several strategic organizational changes designed to better position the company to achieve its global sales and marketing goals as outlined in its discussion of recent quarterly results. Jed Doyle has been moved from Executive Vice President - Operations to the newly-created position of Executive Vice President - Emerging Markets, and John Allbery, who has been working with the Company as a consultant and overseeing European operations, will join the Company in the second quarter 2001 to be in charge of global operations.

In other changes, Mohsen Orodpour, formerly Manager - Western District Sales has been promoted to Director - United States Sales, while Kraig McKee has resigned as Vice President - United States Sales. Mr. McKee has entered into a consulting agreement with Transgenomic in order to ensure a smooth management transition. Kelly Knepfel has joined the company as Manager - Customer Support Services. Ms. Knepfel comes to Transgenomic from Dionex, Inc. where she was Western Region Service Manager.

In speaking of separating the U.S.sales and customer support functions into two distinct positions, Collin D'Silva, CEO stated, "These two positions will help serve our growing customer base with added focus on sales and customer service. These positions are part of our continuing efforts to organize our global direct sales and support operations." Regarding all organizational changes announced today, D'Silva stated that they will help create the structure to allow for continued consistent strong growth in Transgenomic. He also added that the framework to execute the Company's business model both on a tactical and strategic basis necessitated these changes.

About Transgenomic

Transgenomic provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variation in the human genetic code, or genome, in order to accelerate and improve drug development and diagnostics. The company believes its WAVE® System will become a leading tool to analyze genetic mutations. The WAVE® System allows researchers to analyze both known and unknown genetic mutations faster, with more accuracy and at a lower cost than other commercially available techniques.

As efforts to sequence the human genome near completion, understanding variations in the genetic sequence, or mutation analysis, is becoming the vital link to the development of new diagnostic and therapeutic products. By comparing genetic mutations in the genome to the occurrence of diseases or particular traits, correlation can be made between genes and specific diseases or traits. The WAVE® System, unlike tools employing more conventional technologies, can detect these genetic mutations without previous knowledge of their existence or position. As a result, the WAVE® System provides researchers a more accurate and efficient means of performing the experiments necessary to identify mutations and to correlate the relationships between mutations and diseases.

Forward-Looking Statement

This press release may contain forward-looking statements that reflect management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results. Such statements are subject to certain factors, risks and uncertainties described from time to time in Transgenomic, Inc.'s reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release.

For more information, contact: